Patent intelligence · DE
DE 10341317
Mittel zur transdermalen Applikation
Mittel zur transdermalen Applikation
Patent details — DE 10341317
- Jurisdiction
- DE
- Status
- expired
- Grant date
- Mar 31, 2005
- Expiration
- Mar 26, 2025
- Applicant
- NEUROBIOTEC GMBH [DE]
- CPC classes
- A61K 9/ 70 A I, A61K 31/ 48 A I, A61K 47/ 10 A I, A61K/3148
Quick answer
DE 10341317 (Mittel zur transdermalen Applikation) is held by NEUROBIOTEC GMBH [DE]. Status: expired. Granted Mar 31, 2005. Expires Mar 26, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- NEUROBIOTEC GMBH [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 70 A I, A61K 31/ 48 A I, A61K 47/ 10 A I, A61K/3148, A61K/4710, A61K/97061
More from NEUROBIOTEC GMBH [DE]
Related pharmaceutical patents in our USPTO index.
-
CA 2626142
SOLUTIONS AQUEUSES STABILISEES DE COMPOSES D'ERGOLINE
granted -
DE 102006048130
Transdermales therapeutisches System mit zweiphasigem Freisetzungsprofil
granted -
IT MI20070164
CEROTTO TRANSDERMICO
granted -
DE 102004006048
Pharmazeutische Kombination aus Gadolinium Komplexen und kolloidalen Biopolymeren und deren Verwendung als kontrastverstärkendes Mittel zur i.v. Injektion bzw. i.v. Infusion in der MR Angiographie
expired -
AU 2002363847
1-ALLYL ERGOT ALKALOID DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF FOR PREVENTING AND TREATING MIGRAINE
expired -
EP 1311248
TRANSDERMALES THERAPEUTISCHES SYSTEM ZUR BEHANDLUNG DES RESTLESS-LEGS-SYNDROMS
expired -
EP 1303278
KOMBINATION EINES TRANSDERMALEN THERAPEUTISCHEN SYSTEMS UND EINER ORALEN UND/ODER PARENTERALEN ZUBEREITUNG ENTHALTEND DOPAMINAGONISTEN ZUR BEHANDLUNG DOPAMINERGER ERKRANKUNGEN
expired
Frequently asked questions
What is US patent 10341317?
DE 10341317 (Mittel zur transdermalen Applikation) is held by NEUROBIOTEC GMBH [DE]. Status: expired. Granted Mar 31, 2005. Expires Mar 26, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns DE 10341317?
NEUROBIOTEC GMBH [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does DE 10341317 expire?
Our index shows an expiration date of Mar 26, 2025 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.